| Particulars (Rupees in Crores.) | Sept-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 |
|---|---|---|---|---|---|
Gross Sales | 193.52 | 172.93 | 237.48 | 217.34 | 222.7 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 193.52 | 172.93 | 237.48 | 217.34 | 222.7 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 10.77 | 11.45 | 3.9 | 8.49 | 7.52 |
Total Income | 204.3 | 184.38 | 241.38 | 225.83 | 230.22 |
Total Expenditure | 195 | 158.75 | 209.5 | 190.98 | 192.36 |
PBIDT | 9.3 | 25.62 | 31.88 | 34.85 | 37.85 |
Interest | 3.73 | 3.26 | 3.92 | 3.8 | 3.33 |
PBDT | 5.57 | 22.37 | 27.97 | 31.06 | 34.53 |
Depreciation | 8.9 | 8.65 | 8.87 | 8.61 | 8.63 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0 | 0.06 | 0 | 0 |
Deferred Tax | 0 | 0 | -0.1 | 0 | 0 |
Reported Profit After Tax | -3.33 | 13.71 | 19.13 | 22.45 | 25.9 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | -5.72 | 14.91 | 22.29 | 20.78 | 27.24 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | -5.72 | 14.91 | 22.29 | 20.78 | 27.24 |
EPS (Unit Curr.) | -1.13 | 2.94 | 4.4 | 4.1 | 5.37 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 50.72 | 50.72 | 50.72 | 50.72 | 50.72 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 4.8 | 14.81 | 13.42 | 16.03 | 16.99 |
PBDTM(%) | 2.87 | 12.93 | 11.77 | 14.29 | 15.5 |
PATM(%) | -1.72 | 7.92 | 8.05 | 10.32 | 11.62 |
At around 12.53 PM, Orchid Pharma was trading 5% higher at ₹740.40, against the previous close of ₹705.15 on NSE.
The inspection raised, seven minor observations none related to data integrity, and therefore, the facility remains compliant under stringent regulatory standards.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
